O-([18F]Fluoroethyl)-l-tyrosine
([18F]FET) is actively transported into the brain and cancer
cells by LAT1 and possibly other amino acid transporters, which enables
brain tumor imaging by positron emission tomography (PET). However,
tumor delivery of this probe in the presence of competing amino acids
may be limited by a relatively low affinity for LAT1. The aim of the
present work was to evaluate the meta-substituted
[18F]FET analog m-[18F]FET
and the methyl ester [18F]FET-OMe, which were designed
to improve tumor delivery by altering the physicochemical, pharmacokinetic,
and/or transport properties. Both tracers could be prepared with good
radiochemical yields of 41–56% within 66–90 min. Preclinical
evaluation with [18F]FET as a reference tracer demonstrated
reduced in vitro uptake of [18F]FET-OMe
by U87 glioblastoma cells and no advantage for in vivo tumor imaging. In contrast, m-[18F]FET
showed significantly improved in vitro uptake and
accelerated in vivo tumor accumulation in an orthotopic
glioblastoma model. As such, our work identifies m-[18F]FET as a promising alternative to [18F]FET for brain tumor imaging that deserves further evaluation with
regard to its transport properties and in vivo biodistribution.